Genprex Says Japanese Patent Office Issues Favourable Appeal Decision To Grant Patent Claiming Use Of Reqorsa Gene Therapy In Combination With PD-L1 Antibodies To Treat Cancer

Japanese Patent Covers Acclaim-3 Clinical Trial Combining REQORSA Gene Therapy with Genentech, Inc.'s

Tecentriq®

AUSTIN, Texas, Feb. 23, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Japanese Patent Office has issued a favorable Appeal Decision to grant a patent claiming the use of Reqorsa® Gene Therapy in combination with PD-L1 antibodies to treat cancer. Also, the European Patent Office has issued a Decision to Grant relating to a patent for the combination of REQORSA and PD-1 antibodies to treat cancer. Genprex maintains an exclusive license to these patents. The granting of these patents in key markets will strengthen Genprex's intellectual property portfolio, providing further protection for various therapeutic combinations, including the Acclaim-3 clinical trial for the treatment of small cell lung cancer using REQORSA in combination with PD-L1 antibodies.